Literature DB >> 15723265

Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin.

Cezary Watala1, Justyna Pluta, Jacek Golanski, Marcin Rozalski, Malgorzata Czyz, Zygmunt Trojanowski, Józef Drzewoski.   

Abstract

Reduced effectiveness of the most common antiplatelet drug, acetylsalicylic acid (ASA, aspirin), in diabetes mellitus has been associated with a lowered platelet sensitivity to ASA and related to glycemic control in diabetic patients. Our objectives were (a) to monitor the chemical background of how chronic hyperglycemia affects platelet response to ASA in diabetes and (b) to study a chemical competition between the amount of bound acetyl residues and the extent of protein glycation in blood platelets. Using whole-blood impedance aggregometry and platelet function analyzer (PFA-100) we observed a reduced platelet response to ASA in diabetic patients (14% vs. 79% for PFA-100 collagen-epinephrine occlusion time) and an association between the index of glycemic control and platelet refractoriness to ASA (r(S) = -0.378). Impaired platelet response to ASA was related to enhanced platelet protein glycation (3.6+/-0.4 in diabetes vs. 2.3+/-0.4 micromol fructosamine/microg protein in control) and reduced incorporation of acetyl residue into proteins of platelets from diabetic patients (47.4+/-2.0 in control vs. 33.1+/-0.7 micromol acetyl/microg protein in diabetic subjects). Incubation of blood platelets with increasing concentrations of glucose and ASA under in vitro conditions led to excessive modification in protein amino groups: glucose and ASA competed with each other in the course of nonenzymatic modifications, glycosylation, or acetylation, and their contributions to the occupancy of protein amino groups (R2 = 0.22 for glucose, R2 = 0.43 for ASA) were dependent upon the concentrations of glucose and ASA. Overall the effects of high glucose and high ASA on the overall occupancy of protein free amino groups are not additive. While at higher concentrations ASA overcomes the effects of hyperglycemia and retards glycation, high glucose makes acetylation less efficient, and therefore the resultant chemical modification becomes greatly reduced. In conclusion, diminished susceptibility of various platelet proteins and receptors on blood platelet membranes to acetylation and high ambient glucose might underlie the apparently differentiated sensitivity of blood platelets to ASA and determine platelet "insensitivity to aspirin" in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15723265     DOI: 10.1007/s00109-004-0600-x

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  43 in total

Review 1.  Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance.

Authors:  Scott A McKee; David C Sane; Efthymios N Deliargyris
Journal:  Thromb Haemost       Date:  2002-11       Impact factor: 5.249

2.  Rapid photometric method for estimation of platelet count in blood plasma or platelet suspension.

Authors:  B Walkowiak; E Michalak; W Koziolkiewicz; C S Cierniewski
Journal:  Thromb Res       Date:  1989-12-15       Impact factor: 3.944

3.  Differential effect of aspirin on platelet aggregation in IDDM.

Authors:  T A Mori; R Vandongen; A J Douglas; R K McCulloch; V Burke
Journal:  Diabetes       Date:  1992-03       Impact factor: 9.461

4.  Effects of fibrinogen receptor antagonist GR144053F and aurintricarboxylic acid on platelet activation and degranulation.

Authors:  M Rozalski; M Boncler; J Golanski; C Watala
Journal:  Biochem Pharmacol       Date:  2001-11-15       Impact factor: 5.858

5.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

6.  Is platelet aggregation a more important contributor than platelet adhesion to the overall platelet-related primary haemostasis measured by PFA-100?

Authors:  Cezary Watala; Jacek Golanski; Marcin Rozalski; Magdalena A Boncler; Boguslawa Luzak; Janina Baraniak; Dariusz Korczynski; Wojciech Drygas
Journal:  Thromb Res       Date:  2003-03-15       Impact factor: 3.944

Review 7.  Platelets, vascular disease, and diabetes mellitus.

Authors:  P D Winocour
Journal:  Can J Physiol Pharmacol       Date:  1994-03       Impact factor: 2.273

8.  Inhibition of lens crystallin glycation and high molecular weight aggregate formation by aspirin in vitro and in vivo.

Authors:  M S Swamy; E C Abraham
Journal:  Invest Ophthalmol Vis Sci       Date:  1989-06       Impact factor: 4.799

9.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.

Authors:  Patricia A Gum; Kandice Kottke-Marchant; Patricia A Welsh; Jennifer White; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

10.  Quantitation of epsilon-amino group using amino acids as reference standards by trinitrobenzene sulfonic acid. A simple spectrophotometric method for the estimation of hapten to carrier protein ratio.

Authors:  R B Sashidhar; A K Capoor; D Ramana
Journal:  J Immunol Methods       Date:  1994-01-03       Impact factor: 2.303

View more
  22 in total

Review 1.  Old and new molecular mechanisms associated with platelet resistance to antithrombotics.

Authors:  Antonio J López Farré; Juan Tamargo; Petra J Mateos-Cáceres; Luís Azcona; Carlos Macaya
Journal:  Pharm Res       Date:  2010-07-14       Impact factor: 4.200

2.  Aspirin resistance and diabetes mellitus.

Authors:  R Ajjan; R F Storey; P J Grant
Journal:  Diabetologia       Date:  2008-03       Impact factor: 10.122

Review 3.  Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors.

Authors:  Sergio Coccheri
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

Review 4.  TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus.

Authors:  Francesca Santilli; Luciana Mucci; Giovanni Davì
Journal:  Intern Emerg Med       Date:  2010-08-24       Impact factor: 3.397

5.  Aspirin resistance in patients with acute ischemic stroke.

Authors:  Serkan Ozben; Beste Ozben; Azra Meryem Tanrikulu; Feriha Ozer; Tomris Ozben
Journal:  J Neurol       Date:  2011-04-21       Impact factor: 4.849

Review 6.  Antiplatelet resistance in stroke.

Authors:  Mehmet Akif Topçuoglu; Ethem Murat Arsava; Hakan Ay
Journal:  Expert Rev Neurother       Date:  2011-02       Impact factor: 4.618

Review 7.  Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.

Authors:  Dominick J Angiolillo
Journal:  Diabetes Care       Date:  2009-04       Impact factor: 17.152

Review 8.  Approaches to prevention of cardiovascular complications and events in diabetes mellitus.

Authors:  Sergio Coccheri
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome.

Authors:  Yochai Birnbaum; Dat Tran; Mandeep Bajaj; Yumei Ye
Journal:  Basic Res Cardiol       Date:  2019-08-06       Impact factor: 17.165

Review 10.  Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies.

Authors:  Gaia Spinetti; Nicolle Kraenkel; Costanza Emanueli; Paolo Madeddu
Journal:  Cardiovasc Res       Date:  2008-02-15       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.